Previous studies using similar models of PDAC have demonstrated effective tumor control via the use of a combination of agonistic CD137 antibodies, PD-1 blockade, agonistic CD40 antibodies, and TLR stimulation. The gene discussed is CD40; the disease is neoplasm.